Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Tolsura (SUBA-itraconazole)
i
Other names:
SUBA-Cap
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Inhibitor Therap, Mayne Pharma
Drug class:
Hedgehog cell-signalling pathway inhibitor
Related drugs:
‹
vismodegib (14)
sonidegib (11)
GANT61 (2)
cyclopamine (2)
IPI 926 oral (2)
glasdegib (1)
GANT1 (1)
BMS-833923 (0)
GT1708F (0)
Oxy210 (0)
IPI-926 topical (0)
ENV 101 (0)
vismodegib (14)
sonidegib (11)
GANT61 (2)
cyclopamine (2)
IPI 926 oral (2)
glasdegib (1)
GANT1 (1)
BMS-833923 (0)
GT1708F (0)
Oxy210 (0)
IPI-926 topical (0)
ENV 101 (0)
›
Associations
News
Trials
Filter by
Latest
12ms
HITMAN: Phase I/II Study of Hydroxychloroquine With Itraconazole With Biochemically Recurrent Prostate Cancer (clinicaltrials.gov)
P1/2, N=12, Completed, St Vincent's Hospital, Sydney | Active, not recruiting --> Completed | Trial completion date: Jul 2024 --> Oct 2023 | Trial primary completion date: Mar 2023 --> Aug 2023
12 months ago
Trial completion • Trial completion date • Trial primary completion date
|
hydroxychloroquine • Tolsura (SUBA-itraconazole)
over4years
Open-label Trial of SUBA™-Itraconazole (SUBA-Cap) in Subjects With Basal Cell Carcinoma Nevus Syndrome (BCCNS) (clinicaltrials.gov)
P2b, N=38, Completed, HedgePath Pharmaceuticals, Inc. | Active, not recruiting --> Completed
over 4 years ago
Clinical • Trial completion
|
GLI1 (GLI Family Zinc Finger 1)
|
GLI1 expression
|
Tolsura (SUBA-itraconazole)
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login